| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Monique P Curran, Caroline M Perr. Spotlight on amisulpride in schizophrenia. CNS drugs. vol 16. issue 3. 2002-05-03. PMID:11888341. |
in comparative trials, amisulpride administered within this range (400 to 1200 mg/day) was as effective as haloperidol 5 to 40 mg/day, flupenthixol 25 mg/day and risperidone 8 mg/day in patients with acute exacerbations of schizophrenia with predominantly positive symptoms. |
2002-05-03 |
2023-08-12 |
Not clear |
| Monique P Curran, Caroline M Perr. Spotlight on amisulpride in schizophrenia. CNS drugs. vol 16. issue 3. 2002-05-03. PMID:11888341. |
amisulpride is effective as maintenance therapy in patients with chronic schizophrenia. |
2002-05-03 |
2023-08-12 |
Not clear |
| M P Curran, C M Perr. Amisulpride: a review of its use in the management of schizophrenia. Drugs. vol 61. issue 14. 2002-04-02. PMID:11735643. |
amisulpride: a review of its use in the management of schizophrenia. |
2002-04-02 |
2023-08-12 |
Not clear |
| M P Curran, C M Perr. Amisulpride: a review of its use in the management of schizophrenia. Drugs. vol 61. issue 14. 2002-04-02. PMID:11735643. |
in comparative trials, amisulpride administered within this range (400 to 1200 mg/day) was as effective as haloperidol 5 to 40 mg/day, flupenthixol 25 mg/day and risperidone 8 mg/day in patients with acute exacerbations of schizophrenia with predominantly positive symptoms. |
2002-04-02 |
2023-08-12 |
Not clear |
| M P Curran, C M Perr. Amisulpride: a review of its use in the management of schizophrenia. Drugs. vol 61. issue 14. 2002-04-02. PMID:11735643. |
amisulpride is effective as maintenance therapy in patients with chronic schizophrenia. |
2002-04-02 |
2023-08-12 |
Not clear |
| F Pedrosa Gil, R Grohmann, E Rüthe. Asymptomatic bradycardia associated with amisulpride. Pharmacopsychiatry. vol 34. issue 6. 2002-03-12. PMID:11778148. |
here, we will report on a case of asymptomatic bradycardia that developed subsequent to therapeutic doses of amisulpride in a 25-year-old male patient with chronic paranoid-hallucinatory schizophrenia. |
2002-03-12 |
2023-08-12 |
Not clear |
| Y Lecrubier, M Azorin, T Bottai, J Dalery, G Garreau, T Lempérière, A Lisoprawski, F Petitjean, J M Vanell. Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia. Neuropsychobiology. vol 44. issue 1. 2001-08-30. PMID:11408792. |
consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. |
2001-08-30 |
2023-08-12 |
human |
| Y Lecrubier, M Azorin, T Bottai, J Dalery, G Garreau, T Lempérière, A Lisoprawski, F Petitjean, J M Vanell. Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia. Neuropsychobiology. vol 44. issue 1. 2001-08-30. PMID:11408792. |
the french experience emphasizes the central role of amisulpride as a first-line treatment of schizophrenia. |
2001-08-30 |
2023-08-12 |
human |
| X Xiberas, J L Martinot, L Mallet, E Artiges, M Canal, C Loc'h, B Mazière, M L Paillère-Martino. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 2. 2001-07-19. PMID:11270918. |
in vivo extrastriatal and striatal d2 dopamine receptor blockade by amisulpride in schizophrenia. |
2001-07-19 |
2023-08-12 |
human |
| X Xiberas, J L Martinot, L Mallet, E Artiges, M Canal, C Loc'h, B Mazière, M L Paillère-Martino. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 2. 2001-07-19. PMID:11270918. |
ten patients with schizophrenia treated with amisulpride over a wide range of doses (25-1,200 mg/day) were studied. |
2001-07-19 |
2023-08-12 |
human |
| R Kerwi. From pharmacological profiles to clinical outcomes. International clinical psychopharmacology. vol 15 Suppl 4. 2001-06-07. PMID:11252517. |
this unique pharmacology is consistent with the therapeutic profile of amisulpride, which has been clearly demonstrated to control both the positive and negative symptoms of schizophrenia with equal efficacy as well as being well tolerated. |
2001-06-07 |
2023-08-12 |
Not clear |
| J Peusken. Switching approach in the management of schizophrenia patients. International clinical psychopharmacology. vol 15 Suppl 4. 2001-06-07. PMID:11252519. |
patients who have gained weight on previous therapy, or who have negative symptoms of schizophrenia and depressive symptoms, are particularly likely to benefit from amisulpride. |
2001-06-07 |
2023-08-12 |
Not clear |
| J M Azori. Acute phase of schizophrenia: impact of atypical antipsychotics. International clinical psychopharmacology. vol 15 Suppl 4. 2001-06-07. PMID:11252521. |
amisulpride therefore fulfils all the requirements of a first-line agent for the treatment of the acute phase of schizophrenia. |
2001-06-07 |
2023-08-12 |
Not clear |
| O Bli. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation? L'Encephale. vol 26 Spec No 1. 2001-05-17. PMID:11294060. |
on the other hand, amisulpride demonstrate efficacy in the treatment of classical form of schizophrenia at higher doses (400 to 800 mg/day up to 1,200 mg/day at the maximum). |
2001-05-17 |
2023-08-12 |
Not clear |
| O Bli. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation? L'Encephale. vol 26 Spec No 1. 2001-05-17. PMID:11294060. |
therefore, amisulpride is proposed for first-line treatment of schizophrenia in acute exacerbations. |
2001-05-17 |
2023-08-12 |
Not clear |
| M W Agelink, T Majewski, C Wurthmann, K Lukas, H Ullrich, T Linka, E Kliese. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. Journal of clinical psychopharmacology. vol 21. issue 1. 2001-03-01. PMID:11199953. |
as part of a prospective clinical study investigating the effects of atypical neuroleptics on autonomic neurocardiac function (anf), serial standardized recordings of conventional electrocardiograms and computer-calculated measurements of 5-minute resting heart rate variability (hrv) were obtained from 51 medication-free inpatients with schizophrenia (dsm-iii-r-diagnosed) before and after an average of 14.1 days of treatment with amisulpride 400 mg/day (n = 12), olanzapine 20 mg/day (n = 13), sertindole 12 mg/day (n = 13), or clozapine 100 mg/day (n = 13). |
2001-03-01 |
2023-08-12 |
Not clear |
| P Carrière, D Bonhomme, T Lempérièr. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). European psychiatry : the journal of the Association of European Psychiatrists. vol 15. issue 5. 2000-10-11. PMID:11032464. |
amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the amisulpride study group). |
2000-10-11 |
2023-08-12 |
Not clear |
| P Carrière, D Bonhomme, T Lempérièr. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). European psychiatry : the journal of the Association of European Psychiatrists. vol 15. issue 5. 2000-10-11. PMID:11032464. |
in a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months. |
2000-10-11 |
2023-08-12 |
Not clear |
| P Carrière, D Bonhomme, T Lempérièr. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). European psychiatry : the journal of the Association of European Psychiatrists. vol 15. issue 5. 2000-10-11. PMID:11032464. |
in conclusion, amisulpride is globally superior to haloperidol in the treatment of acute exacerbations of schizophrenia and significantly improves patients' quality of life and social adjustment. |
2000-10-11 |
2023-08-12 |
Not clear |
| L Colonna, P Saleem, L Dondey-Nouvel, W Rei. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. International clinical psychopharmacology. vol 15. issue 1. 2000-09-25. PMID:10836281. |
long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. |
2000-09-25 |
2023-08-12 |
Not clear |